出版应用/物种/样本/稀释 | 参考文献 |
---|
| Wedge M, Jennings V, Crupi M, Poutou J, Jamieson T, Pelin A, et al. Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. Nat Commun. 2022;13:1898 pubmed 出版商
|
- 流式细胞仪; 小鼠; 1:250; 图 2c, 7a
| Kharkwal S, Johndrow C, Veerapen N, Kharkwal H, Saavedra Avila N, Carreño L, et al. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy. Cancer Res. 2021;81:1788-1801 pubmed 出版商
|
| Zhang S, Liang W, Luo L, Sun S, Wang F. The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology. BMC Biol. 2020;18:29 pubmed 出版商
|
| Sato Y, Bolzenius J, Eteleeb A, Su X, Maher C, Sehn J, et al. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight. 2018;3: pubmed 出版商
|
| Zippelius A, Schreiner J, Herzig P, Müller P. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015;3:236-44 pubmed 出版商
|
| Dai M, Yip Y, Hellstrom I, Hellstrom K. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res. 2015;21:1127-38 pubmed 出版商
|
| Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2:741-55 pubmed 出版商
|
| Condamine T, Kumar V, Ramachandran I, Youn J, Celis E, Finnberg N, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014;124:2626-39 pubmed 出版商
|
| Redmond W, Linch S, Kasiewicz M. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res. 2014;2:142-53 pubmed 出版商
|
| Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS ONE. 2013;8:e84927 pubmed 出版商
|
| Bulliard Y, Jolicoeur R, Windman M, Rue S, Ettenberg S, Knee D, et al. Activating Fc ? receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210:1685-93 pubmed 出版商
|
| Dai M, Wei H, Yip Y, Feng Q, He K, Popov V, et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother. 2013;36:248-57 pubmed 出版商
|
| Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank C. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology. 2012;1:609-617 pubmed
|
| Balachandran V, Cavnar M, Zeng S, Bamboat Z, Ocuin L, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094-100 pubmed 出版商
|
| Curran M, Kim M, Montalvo W, Al Shamkhani A, Allison J. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS ONE. 2011;6:e19499 pubmed 出版商
|